SEARCH

SEARCH BY CITATION

References

  • 1
    Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994; 151: 5461
  • 2
    Saigal CS, Wessells H, Pace J, Schonlau M, Wilt TJ. Predictors and prevalence of erectile dysfunction in a racially diverse population. Arch Intern Med 2006; 166: 207212
  • 3
    Laumann EO, West S, Glasser D, Carson C, Rosen R, Kang JH. Prevalence and correlates of erectile dysfunction by race and ethnicity among men aged 40 or older in the United States: from the male attitudes regarding sexual health survey. J Sex Med 2007; 4: 5765
  • 4
    Feldman HA, Johannes CB, Derby CA et al. Erectile dysfunction and coronary risk factors: prospective results from the Massachusetts male aging study. Prev Med 2000; 30: 328338
  • 5
    Londono DC, Slezak JM, Quinn VP, Van Den Eeden SK, Loo RK, Jacobsen SJ. Population-based study of erectile dysfunction and polypharmacy. BJU Int 2012; 110: 254259
  • 6
    Bacon CG, Mittleman MA, Kawachi I, Giovannucci E, Glasser DB, Rimm EB. Sexual function in men older than 50 years of age: results from the health professionals follow-up study. Ann Intern Med 2003; 139: 161168
  • 7
    Francis ME, Kusek JW, Nyberg LM, Eggers PW. The contribution of common medical conditions and drug exposures to erectile dysfunction in adult males. J Urol 2007; 178: 591596; discussion 596
  • 8
    Baumhakel M, Schlimmer N, Kratz M, Hackett G, Jackson G, Bohm M. Cardiovascular risk, drugs and erectile function–a systematic analysis. Int J Clin Pract 2011; 65: 289298
  • 9
    Derby CA, Barbour MM, Hume AL, McKinlay JB. Drug therapy and prevalence of erectile dysfunction in the Massachusetts Male Aging Study cohort. Pharmacotherapy 2001; 21: 676683
  • 10
    Gleason JM, Slezak JM, Jung H et al. Regular nonsteroidal anti-inflammatory drug use and erectile dysfunction. J Urol 2011; 185: 13881393
  • 11
    Shiri R, Koskimaki J, Hakkinen J, Tammela TL, Auvinen A, Hakama M. Effect of nonsteroidal anti-inflammatory drug use on the incidence of erectile dysfunction. J Urol 2006; 175: 18121815; discussion 1815–6
  • 12
    Hall SA, Kupelian V, Rosen RC et al. Is hyperlipidemia or its treatment associated with erectile dysfunction?: results from the Boston Area Community Health (BACH) Survey. J Sex Med 2009; 6: 14021413
  • 13
    McKinlay JB, Link CL. Measuring the urologic iceberg: design and implementation of the Boston Area Community Health (BACH) Survey. Eur Urol 2007; 52: 389396
  • 14
    Rosen RC, Cappelleri JC, Smith MD, Lipsky J, Pena BM. Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res 1999; 11: 319326
  • 15
    Kelley KE, Kelley TP, Kaufman DW, Mitchell AA. The Slone Drug Dictionary: a research driven pharmacoepidemiology tool. Pharmacoepidemiol Drug Saf 2003; 12: 168169
  • 16
    Washburn RA, Smith KW, Jette AM, Janney CA. The Physical Activity Scale for the Elderly (PASE): development and evaluation. J Clin Epidemiol 1993; 46: 153162
  • 17
    Green LW. Manual for scoring socioeconomic status for research on health behavior. Public Health Rep 1970; 85: 815827
  • 18
    Turvey CL, Wallace RB, Herzog R. A revised CES-D measure of depressive symptoms and a DSM-based measure of major depressive episodes in the elderly. Int Psychogeriatr 1999; 11: 139148
  • 19
    Grobbee DE, Hoes AW. Confounding and indication for treatment in evaluation of drug treatment for hypertension. BMJ 1997; 315: 11511154
  • 20
    Schafer J. Analysis of Incomplete Multivariate Data. London: Chapman and Hall, 1997
  • 21
    Cochran W. Sampling Techniques, 3rd edn. New York: John Wiley and Sons, 1977
  • 22
    Rosen RC, Marin H. Prevalence of antidepressant-associated erectile dysfunction. J Clin Psychiatry 2003; 64 (Suppl. 10): 510
  • 23
    Montgomery SA, Baldwin DS, Riley A. Antidepressant medications: a review of the evidence for drug-induced sexual dysfunction. J Affect Disord 2002; 69: 119140
  • 24
    Labbate LA, Croft HA, Oleshansky MA. Antidepressant-related erectile dysfunction: management via avoidance, switching antidepressants, antidotes, and adaptation. J Clin Psychiatry 2003; 64 (Suppl. 10): 1119
  • 25
    Ganz P. Erectile dysfunction: pathophysiologic mechanisms pointing to underlying cardiovascular disease. Am J Cardiol 2005; 96: 8M12M
  • 26
    Javaroni V, Neves MF. Erectile dysfunction and hypertension: impact on cardiovascular risk and treatment. Int J Hypertens 2012: 111
  • 27
    Doumas M, Tsakiris A, Douma S et al. Factors affecting the increased prevalence of erectile dysfunction in Greek hypertensive compared with normotensive subjects. J Androl 2006; 27: 469477
  • 28
    Roth A, Kalter-Leibovici O, Kerbis Y et al. Prevalence and risk factors for erectile dysfunction in men with diabetes, hypertension, or both diseases: a community survey among 1,412 Israeli men. Clin Cardiol 2003; 26: 2530
  • 29
    Baumhakel M, Schlimmer N, Bohm M. Effect of irbesartan on erectile function in patients with hypertension and metabolic syndrome. Int J Impot Res 2008; 20: 493500
  • 30
    Bohm M, Baumhakel M, Probstfield JL et al. Sexual function, satisfaction, and association of erectile dysfunction with cardiovascular disease and risk factors in cardiovascular high-risk patients: substudy of the ONgoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNT Study in ACE-INtolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND). Am Heart J 2007; 154: 94101
  • 31
    Shiri R, Koskimaki J, Hakkinen J, Auvinen A, Tammela TL, Hakama M. Cardiovascular drug use and the incidence of erectile dysfunction. Int J Impot Res 2007; 19: 208212